Cover Image
Market Research Report
Product code 
1031036

Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial),

Published: | Roots Analysis | 234 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial),
Published: August 31, 2021
Roots Analysis
Content info: 234 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Title:
Cell Therapy Consumables
Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 - 2031.

Overview:

According to the US Food and Drug Administration (FDA), there has been an evident increase in the number of cell and gene therapy products being evaluated in early phases of development. This can further be validated by the observed upsurge in the number of investigational new drug (IND) applications. In fact, more than 800 IND applications have been filed for ongoing clinical studies, indicating remarkable scientific progress and therapeutic promise of these breakthrough drug candidates. However, manufacturing of cell therapies is a complex and capital-intensive process fraught with a wide range of challenges. Some of the key concerns of contemporary innovators include raw material supply constraints, current facility limitations, high cost of ancillary materials (buffers, growth factors and media) used in upstream processes, regulatory and compliance-related issues, and inconsistencies related to quality attributes of the final product. Further, the onset of recent COVID-19 pandemic has created additional challenges for therapy developers, in terms of procuring the required raw materials, by disrupting well-established supply chains.

Recent reports indicate that the global demand for human serum albumin (a key component of cell culture media for use in a multitude of therapeutic and emerging biotech areas) has increased at an annual rate of 10%-15%. On the contrary, the use of animal components is highly disregarded by the US FDA, European Medicines Agency (EMA), and other regulatory bodies on the grounds that they pose an undesirable risk of transmitting infectious agents, such as prions (mad cow disease) and virus (HIV), as well as enable high batch-to-batch variation. Consequently, serum-free and xeno-free media have proven to be a promising alternative to serum derived components. In order to produce quality cellular therapies, several drug developers prefer to rely on third-party service providers for the supply of raw materials, such as cell culture medium, cell isolation kits and cell separation reagents. Presently, over 60 service providers are actively engaged in providing consumable / raw material products for the production of cell therapies. The current consolidated market landscape is primarily dominated by the presence of large players, capturing a substantial proportion of the market share. In the recent past, many of the aforementioned service providers have also forged strategic alliances and / or acquired other players, in order to further enhance their respective service offerings. Given that the demand for cell therapies is indubitably rising, the corresponding opportunity for cell therapy consumable service providers is expected to witness steady growth, over the next decade.

Scope of the Report:

The "Cell Therapy Consumables Market by Type of Consumable (Kits, Media and Reagents), Type of Cell Therapy (Dendritic Cell Therapy, NK Cell Therapy, Stem Cell Therapy and T-Cell Therapy), Scale of Operation (Clinical and Commercial), Type of End-User (Industry and Non-Industry) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2021 - 2031" report features an extensive study on the consumable providers within the cell therapy industry. The study also includes an elaborate discussion on the future potential of this evolving market. Amongst other elements, the report features:

  • A detailed overview of the overall market landscape of players engaged in offering cell therapy consumables, along with information on several relevant parameters, such as year of establishment, company size, location of headquarters, number and location of consumable facilities, type of consumable (kits, media and reagents) , type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy) , application area (research use and therapeutic use), scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry) .
  • An in-depth company competitiveness analysis of cell therapy consumable service providers based on their product portfolio strength (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) , service strength (based on its experience and company size) and number of products offered.
  • A detailed brand positioning analysis of prominent industry players (shortlisted on the basis of strength of service portfolio) , highlighting the current perceptions regarding their proprietary brands across different consumable classes.
  • Elaborate profiles of the key players offering cell therapy consumable products. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.
  • An analysis of recent developments within the cell therapy consumable industry, highlighting information on several partnerships and collaborations, mergers and acquisitions, and expansion initiatives that have taken place in this domain, during the period 2016-2021.
  • A list of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field) , pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) , manufacturing facilities and availability of other cell therapy capabilities.
  • An informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells) , based on type of cell therapy and key geographical regions.
  • An elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and the future opportunity associated within the cell therapy consumables market, over the next decade. We have developed an informed estimate of the financial evolution of the market, over the period 2021-2031. Additionally, the report features the likely distribution of the current and forecasted opportunity across [A] type of consumable (kits, media and reagents) , [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy) , [C] scale of operation (clinical and commercial) , [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) . In order to account for future uncertainties associated with some of the key parameters and to add robustness to our forecast model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic tracks of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the key players, across the world, engaged in offering consumables for cell therapies?
  • Which regions have emerged as key hubs in terms of cell therapy consumable related capabilities?
  • Which are the most popular media components used for cell therapy consumables?
  • What kind of partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the recent COVID-19 pandemic likely to impact the consumables market for cell therapies?
  • What are the key challenges associated with cell therapy consumables?
  • What is the current, global demand (kits, media and reagents) for cell therapy consumables in the manufacturing process?
  • How is the current and future market opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to consumables market for cell therapies?

Chapter Outlines:

Chapter 2 is an executive summary of key insights captured in our research. It offers a high-level view on the current state of the cell therapy consumables market and its likely evolution in the short to mid-term and long-term.

Chapter 3 provides a general introduction to cell therapies. It further includes a detailed discussion on the development and manufacturing process of cell therapies, along with information on the role of raw materials in cell therapy manufacturing. Furthermore, it provides a brief overview of the different types of cell therapy consumables and key challenges associated with their development.

Chapter 4 provides a detailed overview of the cell therapy consumables landscape. It includes information related to over 60 industry players that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as year of establishment, company size, location of headquarters, location of consumable facilities, type of consumable (kits, media and reagents), type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy) , application area (research use and therapeutic use) , scale of operation (preclinical, clinical and commercial) and type of end-user (industry and non-industry) .

Chapter 5 features an insightful company competitiveness analysis, highlighting prominent consumable service providers, taking into consideration service strength of a company (based on its experience and company size) , product portfolio (number of type of consumable, number of unique type of cell therapy, number of consumable facilities and application area) and number of products.

Chapter 6 provides an elaborative brand positioning analysis of the leading industry players (shortlisted on the basis of strength of service portfolio) , highlighting the current perceptions regarding their proprietary brands across different consumable classes.

Chapter 7 provides elaborate profiles of key service providers (shortlisted on the basis of the company competitiveness analysis) engaged in this domain. Each profile features a brief overview of the company, details related to cell therapy consumable focused product portfolio, consumable facilities, recent developments and an informed future outlook.

Chapter 8 provides detailed analysis of the recent developments and initiatives (partnerships and collaborations, mergers and acquisitions and expansions) that have been undertaken in the cell therapy consumable industry, during the period between 2016 and 2021.

Chapter 9 features an in-depth analysis of over 310 cell therapy developers that are anticipated to partner with cell therapy consumable providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account a company's size and its experience in this field) , pipeline strength and maturity (based on the number of pipeline drugs and affiliated stage of development) , manufacturing facilities and availability of other cell therapy capabilities.

Chapter 10 provides an informed estimate of the annual demand for cell therapy consumables (in terms of volume of media required for total number of cells) , based on type of cell therapy and key geographical regions.

Chapter 11 presents an insightful market forecast analysis, highlighting the future potential of cell therapy consumables market till 2031. We have segmented the market on the basis of [A] type of consumable (kits, media and reagents) , [B] type of cell therapy (dendritic cell therapy, NK cell therapy, stem cell therapy and T-cell therapy) , [C] scale of operation (clinical and commercial) , [D] type of end-user (industry and non-industry) and [E] key geographical regions (North America, Europe, Asia-Pacific and Rest of the World) .

Chapter 12 features an elaborate discussion on the future opportunities / trends within the cell therapy consumables market that are likely to influence the growth of this domain over the coming years.

Chapter 13 highlights the effects of the recent COVID-19 pandemic on the consumables market for cell therapies, along with information on the key initiatives undertaken by various service providers in order to overcome the challenges faced due to the pandemic.

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion of the cell therapy consumables market, based on the research and analysis described in the previous chapters.

Chapter 15 is a collection of transcripts of interviews conducted with various stakeholders in the industry.

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Table of Contents

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

  • 2.1. Chapter Overview

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Chapter Overview
  • 3.3. Introduction to Cell Therapies
    • 3.3.1. Comparison of Cell Therapies and Other Biotechnology Products
  • 3.4. Classification of Cell Therapy Products
  • 3.5. Overview of Cell Therapy Development and Manufacturing
  • 3.6. Role of Raw Materials in Cell Therapy Development
  • 3.7. Type of Cell Therapy Consumable
  • 3.8. Key Challenges Associated with Cell Therapy Consumables
  • 3.9. Future Perspectives

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cell Therapy Kit Providers: List of Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Kits Preparation Facilities
    • 4.2.5. Analysis by Accreditations Received
    • 4.2.6. Analysis by Type of End-User
    • 4.2.7. Analysis by Type of Cell Therapy
    • 4.2.8. Analysis by Type of Function
    • 4.2.9. Analysis by Scale of Operation
  • 4.2.10. Analysis by Application Area
  • 4.2.11. Analysis by Application Area and Geography (Regional Landscape)
  • 4.3. Cell Therapy Media Providers: List of Players
    • 4.3.1. Analysis by Year of Establishment
    • 4.3.2. Analysis by Company Size
    • 4.3.3. Analysis by Location of Headquarters
    • 4.3.4. Analysis by Location of Media Preparation Facilities
    • 4.3.5. Analysis by Accreditations Received
    • 4.3.6. Analysis by Type of End-User
    • 4.3.7. Analysis by Type of Cell Therapy
    • 4.3.8. Analysis by Media Components
    • 4.3.9. Analysis by Type of Function
  • 4.3.10. Analysis by Scale of Operation
  • 4.3.11. Analysis by Application Area
  • 4.3.12. Analysis by Application Area and Geography (Regional Landscape)
  • 4.4. Cell Therapy Reagent Providers: List of Players
    • 4.4.1. Analysis by Year of Establishment
    • 4.4.2. Analysis by Company Size
    • 4.4.3. Analysis by Location of Headquarters
    • 4.4.4. Analysis by Location of Reagent Preparation Facilities
    • 4.4.5. Analysis by Accreditations Received
    • 4.4.6. Analysis by Type of End-User
    • 4.4.7. Analysis by Type of Cell Therapy
    • 4.4.8. Analysis by Type of Function
    • 4.4.9. Analysis by Scale of Operation
  • 4.4.10. Analysis by Application Area
  • 4.4.11. Analysis by Application Area and Geography (Regional Landscape)
  • 4.5. Analysis by Type of Consumable, Type of Cell Therapy and Application Area (Grid Representation)

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Key Assumptions and Parameters
  • 5.3. Methodology
  • 5.4. Company Competitiveness: Kit Providers
  • 5.5. Company Competitiveness: Media Providers
  • 5.6. Company Competitiveness: Reagent Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Bio-Techne
  • 6.4. Miltenyi Biotec
  • 6.5. Sartorius
  • 6.6. STEMCELL Technologies
  • 6.7. Thermo Fisher Scientific

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. Miltenyi Biotec
    • 7.2.1. Company Overview
    • 7.2.2. Product Portfolio
    • 7.2.3. Recent Developments and Future Outlook
  • 7.3. STEMCELL Technologies
    • 7.3.1. Company Overview
    • 7.3.2. Product Portfolio
    • 7.3.3. Recent Developments and Future Outlook
  • 7.4. Bio-Techne
    • 7.4.1. Company Overview
    • 7.4.2. Product Portfolio
    • 7.4.3. Recent Developments and Future Outlook
  • 7.5. Irvine Scientific
    • 7.5.1. Company Overview
    • 7.5.2. Product Portfolio
    • 7.5.3. Recent Developments and Future Outlook
  • 7.6. Thermo Fisher Scientific
    • 7.6.1. Company Overview
    • 7.6.2. Product Portfolio
    • 7.6.3. Recent Developments and Future Outlook
  • 7.7. Sartorius
    • 7.7.1. Company Overview
    • 7.7.2. Product Portfolio
    • 7.7.3. Recent Developments and Future Outlook
  • 7.8. BD Biosciences
    • 7.8.1. Company Overview
    • 7.8.2. Product Portfolio
    • 7.8.3. Recent Developments and Future Outlook
  • 7.9. Lonza
    • 7.9.1. Company Overview
    • 7.9.2. Product Portfolio
    • 7.9.3. Recent Developments and Future Outlook
  • 7.10. CellGenix
    • 7.10.1. Company Overview
    • 7.10.2. Product Portfolio
    • 7.10.3. Recent Developments and Future Outlook
  • 7.11. Corning
    • 7.11.1. Company Overview
    • 7.11.2. Product Portfolio
    • 7.11.3. Recent Developments and Future Outlook

8. RECENT DEVELOPMENTS AND INITIATIVES

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Cell Therapy Consumables: Recent Partnerships and Collaborations
    • 8.3.1. Analysis by Year of Partnership
    • 8.3.2. Analysis by Type of Partnership
    • 8.3.3. Analysis by Year and Type of Partnership
    • 8.3.4. Analysis by Type of Consumable
    • 8.3.5. Analysis by Type of Partnership and Type of Consumable
    • 8.3.6. Analysis by Type of Cell Therapy
    • 8.3.7. Analysis by Type of Consumable and Type of Cell Therapy
    • 8.3.8. Most Active Players: Analysis by Number of Partnerships
    • 8.3.9. Analysis by Region
      • 8.3.9.1. Intracontinental and Intercontinental Agreements
      • 8.3.9.2. Local and International Agreements
  • 8.3.10. Cumulative Year-wise Trend of Merger / Acquisition
  • 8.3.11. Analysis by Type of Acquisition
  • 8.3.12. Analysis by Key Value Drivers
  • 8.3.13. Analysis by Year of Acquisition and Key Value Drivers
  • 8.4. Cell Therapy Consumables: Recent Expansions
    • 8.4.1. Analysis by Year of Expansion
    • 8.4.2. Analysis by Purpose of Expansion
    • 8.4.3. Analysis by Year and Purpose of Expansion
    • 8.4.4. Analysis by Type of Consumable
    • 8.4.5. Analysis by Purpose of Expansion and Type of Consumable
    • 8.4.6. Analysis by Area of Expansion
    • 8.4.7. Analysis by Region
      • 8.4.7.1. Analysis by Location of Consumable Facility (Continent-wise)
      • 8.4.7.2. Analysis by Location of Consumable Facility (Country-wise)
    • 8.4.8. Analysis by Purpose of Expansion and Location of Headquarters

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS

  • 9.1. Chapter Overview
  • 9.2. Scoring Criteria and Key Assumptions
  • 9.3. Scope and Methodology
  • 9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers
    • 9.3.1. Likely Partner Opportunities for Dendritic Cell Therapy Consumable Providers
    • 9.3.2. Likely Partner Opportunities for NK Cell Therapy Consumable Providers
    • 9.3.3. Likely Partner Opportunities for Stem Cell Therapy Consumable Providers
    • 9.3.4. Likely Partner Opportunities for T-Cell Therapy Consumable Providers

10. DEMAND ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Scope and Methodology
  • 10.3. Global Demand for Cell Therapy Consumables
  • 10.4. Global Demand for Cell Therapy Consumables for Planar Processes
  • 10.5. Global Demand for Cell Therapy Consumables for Suspension Processes
  • 10.6. Analysis by Scale of Operation
  • 10.7. Analysis by Region

11. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Forecast Methodology
  • 11.3. Global Outsourced Cell Therapy Consumables Market, 2021-2031
  • 11.4. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Consumable
    • 11.4.1. Outsourced Cell Therapy Consumables Market for Kits, 2021-2031
    • 11.4.2. Outsourced Cell Therapy Consumables Market for Media, 2021-2031
    • 11.4.3. Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031
  • 11.5. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of Cell Therapy
    • 11.5.1. Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031
    • 11.5.2. Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031
    • 11.5.3. Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031
    • 11.5.4. Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031
  • 11.6. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Scale of Operation
    • 11.6.1. Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031
    • 11.6.2. Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031
  • 11.7. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Type of End-User
    • 11.7.1. Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031
    • 11.7.2. Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031
  • 11.8. Outsourced Cell Therapy Consumables Market, 2021-2031: Distribution by Geography
    • 11.8.1. Outsourced Cell Therapy Consumables Market in North America, 2021-2031
    • 11.8.2. Outsourced Cell Therapy Consumables Market in Europe, 2021-2031
    • 11.8.3. Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031
    • 11.8.4. Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031

12. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES

  • 12.1. Chapter Overview
  • 12.2. Emerging Trends Related to Cell Culture Media
  • 12.3. Automation of Cell Therapy Manufacturing Processes
  • 12.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

13. IMPACT OF COVID-19 ON CELL THERAPY CONSUMABLES MARKET

  • 13.1. Chapter Overview
  • 13.2. Impact of COVID-19 Pandemic on Cell Therapy Consumables Market
  • 13.3. Impact on Future Market Opportunities for Cell Therapy Consumable Providers
  • 13.4. Current Opinions and Key Initiatives of Key Players
  • 13.5. Recuperative Strategies for Developer Businesses
    • 13.5.1. Strategies for Implementation in the Short / Mid Term
    • 13.5.2. Strategies for Implementation in the Long Term

14. CONCLUDING REMARKS

  • 14.1. Chapter Overview

15. INTERVIEW TRANSCRIPTS

  • 15.1. Chapter Overview
  • 15.2. Anant Kamath, Chief Operating Officer, Cellular Engineering Technologies
    • 15.2.1. Cellular Engineering Technologies: Key Highlights
    • 15.2.2. Interview Transcript
  • 15.3. Vishal G. Warke, Director R&D, Cell Culture and Immunology, HiMedia Laboratories and Gauri W. Page, Assistant R&D Manager, Animal Cell Culture, Himedia Laboratories
    • 15.3.1. HiMedia Laboratories: Key Highlights
    • 15.3.2. Interview Transcript

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 2.1 Executive Summary: Market Landscape
  • Figure 2.2 Executive Summary: Recent Developments
  • Figure 2.3 Executive Summary: Demand Analysis
  • Figure 2.4 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Type of Cell Therapy Consumable
  • Figure 4.1 Cell Therapy Consumables: Distribution by Type of Consumable
  • Figure 4.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
  • Figure 4.3 Cell Therapy Kit Providers: Distribution by Company Size
  • Figure 4.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
  • Figure 4.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
  • Figure 4.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
  • Figure 4.7 Cell Therapy Kit Providers: Distribution by Type of End-User
  • Figure 4.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
  • Figure 4.9 Cell Therapy Kits: Distribution by Type of Function
  • Figure 4.10 Cell Therapy Kits: Distribution by Scale of Operation
  • Figure 4.11 Cell Therapy Kits: Distribution by Application Area
  • Figure 4.12 Regional Landscape: Distribution of Kit Providers by Application Area and Geography
  • Figure 4.13 Cell Therapy Media Providers: Distribution by Year of Establishment
  • Figure 4.14 Cell Therapy Media Providers: Distribution by Company Size
  • Figure 4.15 Cell Therapy Media Providers: Distribution by Location of Headquarters
  • Figure 4.16 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
  • Figure 4.17 Cell Therapy Media Providers: Distribution by Accreditations Received
  • Figure 4.18 Cell Therapy Media Providers: Distribution by Type of End-User
  • Figure 4.19 Cell Therapy Media: Distribution by Type of Cell Therapy
  • Figure 4.20 Cell Therapy Media: Distribution by Media Components
  • Figure 4.21 Cell Therapy Media: Distribution by Type of Function
  • Figure 4.22 Cell Therapy Media: Distribution by Scale of Operation
  • Figure 4.23 Cell Therapy Media: Distribution by Application Area
  • Figure 4.24 Regional Landscape: Distribution of Media providers by Application Area and Geography
  • Figure 4.25 Cell Therapy Reagent Providers: Distribution by Year of Establishment
  • Figure 4.26 Cell Therapy Reagent Providers: Distribution by Company Size
  • Figure 4.27 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
  • Figure 4.28 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
  • Figure 4.29 Cell Therapy Reagent Providers: Distribution by Accreditations Received
  • Figure 4.30 Cell Therapy Reagent Providers: Distribution by Type of End-User
  • Figure 4.31 Cell Therapy Reagents: Distribution by Type of Cell Therapy
  • Figure 4.32 Cell Therapy Reagents: Distribution by Type of Function
  • Figure 4.33 Cell Therapy Reagents: Distribution by Scale of Operation
  • Figure 4.34 Cell Therapy Reagents: Distribution by Application Area
  • Figure 4.35 Regional Landscape: Distribution of Reagent Providers by Application Area and Geography
  • Figure 4.36 Grid Representation: Distribution by Type of Consumable, Type of Cell Therapy and Application Area
  • Figure 5.1 Company Competitiveness: Cell Therapy Kit Providers
  • Figure 5.2 Company Competitiveness: Cell Therapy Media Providers
  • Figure 5.3 Company Competitiveness: Cell Therapy Reagent Providers
  • Figure 6.1 Brand Positioning Matrix: Bio-Techne
  • Figure 6.2 Brand Positioning Matrix: Miltenyi Biotec
  • Figure 6.3 Brand Positioning Matrix: Sartorius
  • Figure 6.4 Brand Positioning Matrix: STEMCELL Technologies
  • Figure 6.5 Brand Positioning Matrix: Thermo Fisher Scientific
  • Figure 7.1 Miltenyi Biotec: Product Portfolio
  • Figure 7.2 STEMCELL Technologies: Product Portfolio
  • Figure 7.3 Bio-Techne: Product Portfolio
  • Figure 7.4 Irvine Scientific: Product Portfolio
  • Figure 7.5 Thermo Fisher Scientific: Product Portfolio
  • Figure 7.6 Sartorius: Product Portfolio
  • Figure 7.7 BD Biosciences: Product Portfolio
  • Figure 7.8 Lonza: Product Portfolio
  • Figure 7.9 CellGenix: Product Portfolio
  • Figure 7.10 Corning: Product Portfolio
  • Figure 8.1 Partnerships and Collaborations: Distribution by Year of Partnership
  • Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Figure 8.4 Partnerships and Collaborations: Distribution by Type of Consumable
  • Figure 8.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
  • Figure 8.6 Partnerships and Collaborations: Distribution by Type of Cell Therapy
  • Figure 8.7 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
  • Figure 8.8 Most Active Players: Distribution by Number of Partnerships
  • Figure 8.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
  • Figure 8.10 Partnerships and Collaborations: Local and International Agreements
  • Figure 8.11 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
  • Figure 8.12 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Figure 8.13 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Figure 8.14 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Figure 8.15 Recent Expansions: Distribution by Year of Expansion
  • Figure 8.16 Recent Expansions: Distribution by Purpose of Expansion
  • Figure 8.17 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Figure 8.18 Recent Expansions: Distribution by Type of Consumable
  • Figure 8.19 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
  • Figure 8.20 Recent Expansions: Distribution by Area of Expansion
  • Figure 8.21 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
  • Figure 8.22 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
  • Figure 8.23 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
  • Figure 10.1 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
  • Figure 10.2 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
  • Figure 10.3 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
  • Figure 10.4 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
  • Figure 10.5 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
  • Figure 10.6 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
  • Figure 10.7 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
  • Figure 11.1 Global Outsourced Cell Therapy Consumables Market, 2021-2031 (USD Million)
  • Figure 11.2 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable
  • Figure 11.3 Outsourced Cell Therapy Consumables Market for Kits, 2021-2031 (USD Million)
  • Figure 11.4 Outsourced Cell Therapy Consumables Market for Media, 2021-2031 (USD Million)
  • Figure 11.5 Outsourced Cell Therapy Consumables Market for Reagents, 2021-2031 (USD Million)
  • Figure 11.6 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy
  • Figure 11.7 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, 2021-2031 (USD Million)
  • Figure 11.8 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, 2021-2031 (USD Million)
  • Figure 11.9 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, 2021-2031 (USD Million)
  • Figure 11.10 Outsourced Cell Therapy Consumables Market for T-Cell Therapy, 2021-2031 (USD Million)
  • Figure 11.11 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation
  • Figure 11.12 Outsourced Cell Therapy Consumables Market for Clinical Operations, 2021-2031 (USD Million)
  • Figure 11.13 Outsourced Cell Therapy Consumables Market for Commercial Operations, 2021-2031 (USD Million)
  • Figure 11.14 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User
  • Figure 11.15 Outsourced Cell Therapy Consumables Market for Industry Players, 2021-2031 (USD Million)
  • Figure 11.16 Outsourced Cell Therapy Consumables Market for Non-Industry Players, 2021-2031 (USD Million)
  • Figure 11.17 Outsourced Cell Therapy Consumables Market: Distribution by Region
  • Figure 11.18 Outsourced Cell Therapy Consumables Market in North America, 2021-2031 (USD Million)
  • Figure 11.19 Outsourced Cell Therapy Consumables Market in Europe, 2021-2031 (USD Million)
  • Figure 11.20 Outsourced Cell Therapy Consumables Market in Asia-Pacific, 2021-2031 (USD Million)
  • Figure 11.21 Outsourced Cell Therapy Consumables Market in Rest of the World, 2021-2031 (USD Million)
  • Figure 14.1 Concluding Remarks: Overall Market Overview
  • Figure 14.2 Concluding Remarks: Recent Developments
  • Figure 14.3 Concluding Remarks: Demand Analysis
  • Figure 14.4 Concluding Remarks: Market Sizing and Opportunity Analysis
  • Figure 14.5 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

  • Table 3.1 Cell Therapies: Applications
  • Table 3.2 Differences between Cell Therapy and Biotechnology Product
  • Table 3.3 Key Cell Therapy Manufacturing Steps
  • Table 3.4 Types of Media Used in Cell Therapy Manufacturing
  • Table 7.1 Miltenyi Biotec: Key Highlights
  • Table 7.2 Miltenyi Biotec: Product Portfolio
  • Table 7.3 STEMCELL Technologies: Key Highlights
  • Table 7.4 STEMCELL Technologies: Product Portfolio
  • Table 7.5 STEMCELL Technologies: Recent Developments and Future Outlook
  • Table 7.6 Bio-Techne: Key Highlights
  • Table 7.7 Bio-Techne: Product Portfolio
  • Table 7.8 Bio-Techne: Recent Developments and Future Outlook
  • Table 7.9 Irvine Scientific: Key Highlights
  • Table 7.10 Irvine Scientific: Product Portfolio
  • Table 7.11 Irvine Scientific: Recent Developments and Future Outlook
  • Table 7.12 Thermo Fisher Scientific: Key Highlights
  • Table 7.13 Thermo Fisher Scientific: Product Portfolio
  • Table 7.14 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 7.15 Sartorius: Key Highlights
  • Table 7.16 Sartorius: Product Portfolio
  • Table 7.17 Sartorius: Recent Developments and Future Outlook
  • Table 7.18 BD Biosciences: Key Highlights
  • Table 7.19 BD Biosciences: Product Portfolio
  • Table 7.20 Lonza: Key Highlights
  • Table 7.21 Lonza: Product Portfolio
  • Table 7.22 CellGenix: Key Highlights
  • Table 7.23 CellGenix: Product Portfolio
  • Table 7.24 CellGenix: Recent Developments and Future Outlook
  • Table 7.25 Corning: Key Highlights
  • Table 7.26 Corning: Product Portfolio
  • Table 8.1 Cell Therapy Consumables: List of Partnerships and Collaborations, 2016-2021
  • Table 8.2 Cell Therapy Consumables Partnerships and Collaborations: Information on Type of Agreement (Region-wise and Geography-wise), 2016-2021
  • Table 8.3 Mergers and Acquisitions: Information on Key Value Drivers, 2016-2021
  • Table 8.4 Cell Therapy Consumables: List of Recent Expansions, 2016-2021
  • Table 9.1 Key Potential Strategic Partners for Cell Therapy Consumable Providers
  • Table 9.2 Likely Partners for Dendritic Cell Therapy Consumable Providers
  • Table 9.3 Likely Partners for NK Cell Therapy Consumable Providers
  • Table 9.4 Likely Partners for Stem Cell Therapy Consumable Providers
  • Table 9.5 Likely Partners for T-Cell Therapy Consumable Providers
  • Table 15.1 Cellular Engineering Technologies: Key Highlights
  • Table 15.2 HiMedia Laboratories: Key Highlights
  • Table 16.1 Cell Therapy Consumables: Distribution by Type of Consumable
  • Table 16.2 Cell Therapy Kit Providers: Distribution by Year of Establishment
  • Table 16.3 Cell Therapy Kit Providers: Distribution by Company Size
  • Table 16.4 Cell Therapy Kit Providers: Distribution by Location of Headquarters
  • Table 16.5 Cell Therapy Kit Providers: Distribution by Location of Kit Preparation Facilities
  • Table 16.6 Cell Therapy Kit Providers: Distribution by Accreditations Received
  • Table 16.7 Cell Therapy Kit Providers: Distribution by Type of End-User
  • Table 16.8 Cell Therapy Kits: Distribution by Type of Cell Therapy
  • Table 16.9 Cell Therapy Kits: Distribution by Type of Function
  • Table 16.10 Cell Therapy Kits: Distribution by Scale of Operation
  • Table 16.11 Cell Therapy Kits: Distribution by Application Area
  • Table 16.12 Cell Therapy Media Providers: Distribution by Year of Establishment
  • Table 16.13 Cell Therapy Media Providers: Distribution by Company Size
  • Table 16.14 Cell Therapy Media Providers: Distribution by Location of Headquarters
  • Table 16.15 Cell Therapy Media Providers: Distribution by Location of Media Preparation Facilities
  • Table 16.16 Cell Therapy Media Providers: Distribution by Accreditations Received
  • Table 16.17 Cell Therapy Media Providers: Distribution by Type of End-User
  • Table 16.18 Cell Therapy Media: Distribution by Type of Cell Therapy
  • Table 16.19 Cell Therapy Media: Distribution by Media Components
  • Table 16.20 Cell Therapy Media: Distribution by Type of Function
  • Table 16.21 Cell Therapy Media: Distribution by Scale of Operation
  • Table 16.22 Cell Therapy Media: Distribution by Application Area
  • Table 16.23 Cell Therapy Reagent Providers: Distribution by Year of Establishment
  • Table 16.24 Cell Therapy Reagent Providers: Distribution by Company Size
  • Table 16.25 Cell Therapy Reagent Providers: Distribution by Location of Headquarters
  • Table 16.26 Cell Therapy Reagent Providers: Distribution by Location of Reagent Preparation Facilities
  • Table 16.27 Cell Therapy Reagent Providers: Distribution by Accreditations Received
  • Table 16.28 Cell Therapy Reagent Providers: Distribution by Type of End-User
  • Table 16.29 Cell Therapy Reagents: Distribution by Type of Cell Therapy
  • Table 16.30 Cell Therapy Reagents: Distribution by Type of Function
  • Table 16.31 Cell Therapy Reagents: Distribution by Scale of Operation
  • Table 16.32 Cell Therapy Reagents: Distribution by Application Area
  • Table 16.33 Partnerships and Collaborations: Distribution by Year of Partnership
  • Table 16.34 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 16.35 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partnership
  • Table 16.36 Partnerships and Collaborations: Distribution by Type of Consumable
  • Table 16.37 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Consumable
  • Table 16.38 Partnerships and Collaborations: Distribution by Type of Cell Therapy
  • Table 16.39 Partnerships and Collaborations: Distribution by Type of Consumable and Type of Cell Therapy
  • Table 16.40 Most Active Players: Distribution by Number of Partnerships
  • Table 16.41 Partnerships and Collaborations: Local and International Agreements
  • Table 16.42 Mergers and Acquisitions: Year-wise Cumulative Trend, 2016-2021
  • Table 16.43 Mergers and Acquisitions: Distribution by Type of Acquisition
  • Table 16.44 Mergers and Acquisitions: Distribution by Key Value Drivers
  • Table 16.45 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
  • Table 16.46 Recent Expansions: Distribution by Year of Expansion
  • Table 16.47 Recent Expansions: Distribution by Purpose of Expansion
  • Table 16.48 Recent Expansions: Distribution by Year and Purpose of Expansion
  • Table 16.49 Recent Expansions: Distribution by Type of Consumable
  • Table 16.50 Recent Expansions: Distribution by Purpose of Expansion and Type of Consumable
  • Table 16.51 Recent Expansions: Distribution by Area of Expansion
  • Table 16.52 Recent Expansions: Distribution by Location of Consumable Facility (Continent-wise)
  • Table 16.53 Recent Expansions: Distribution by Location of Consumable Facility (Country-wise)
  • Table 16.54 Recent Expansions: Distribution by Location of Headquarters and Purpose of Expansion
  • Table 16.55 Global Demand for Cell Therapy Consumables, 2021-2026 (Million Liters)
  • Table 16.56 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026 (Million Liters)
  • Table 16.57 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026 (Million Liters)
  • Table 16.58 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
  • Table 16.59 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Scale of Operation (Million Liters)
  • Table 16.60 Global Demand for Cell Therapy Consumables for Planar Process, 2021-2026: Distribution by Region (Million Liters)
  • Table 16.61 Global Demand for Cell Therapy Consumables for Suspension Process, 2021-2026: Distribution by Region (Million Liters)
  • Table 16.62 Global Outsourced Cell Therapy Consumables Market, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.63 Outsourced Cell Therapy Consumables Market: Distribution by Type of Consumable, 2021 and 2030
  • Table 16.64 Outsourced Cell Therapy Consumables Market for Kits, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.65 Outsourced Cell Therapy Consumables Market for Media, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.66 Outsourced Cell Therapy Consumables Market for Reagents, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.67 Outsourced Cell Therapy Consumables Market: Distribution by Type of Cell Therapy, 2021 and 2030
  • Table 16.68 Outsourced Cell Therapy Consumables Market for Dendritic Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.69 Outsourced Cell Therapy Consumables Market for NK Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.70 Outsourced Cell Therapy Consumables Market for Stem Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.71 Outsourced Cell Therapy Consumables Market for T- Cell Therapy, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.72 Outsourced Cell Therapy Consumables Market: Distribution by Scale of Operation, 2021 and 2030
  • Table 16.73 Outsourced Cell Therapy Consumables Market for Clinical Operations, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
  • Table 16.74 Outsourced Cell Therapy Consumables Market for Commercial Operations, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.75 Outsourced Cell Therapy Consumables Market: Distribution by Type of End-User, 2021 and 2030
  • Table 16.76 Outsourced Cell Therapy Consumables Market for Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.77 Outsourced Cell Therapy Consumables Market for Non-Industry Players, Conservative, Base and Optimistic Scenarios, 2021-2031 (USD Million)
  • Table 16.78 Outsourced Cell Therapy Consumables Market: Distribution by Geography, 2021 and 2030
  • Table 16.79 Outsourced Cell Therapy Consumables Market in North America, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
  • Table 16.80 Outsourced Cell Therapy Consumables Market in Europe, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
  • Table 16.81 Outsourced Cell Therapy Consumables Market in Asia-Pacific, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)
  • Table 16.82 Outsourced Cell Therapy Consumables Market in Rest of the World, Conservative, Base and Optimistic Scenario, 2021-2031 (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  • 1. 3P Biopharmaceuticals
  • 2. Accellta
  • 3. Acer Therapeutics
  • 4. Activartis Biotech
  • 5. Adaptimmune
  • 6. Adicet Bio
  • 7. Aduro Biotech
  • 8. Advent Bioservices
  • 9. AGC Biologics
  • 10. AgenTus Therapeutics
  • 11. Agilent Technologies
  • 12. Ajinomoto
  • 13. Akadeum Life Sciences
  • 14. Akron Biotech
  • 15. Allele Biotechnology and Pharmaceuticals
  • 16. Allife Medical Science and Technology
  • 17. Allogene Therapeutics
  • 18. Altor BioScience
  • 19. American CryoStem
  • 20. Amphera
  • 21. AMSBIO
  • 22. Anhui Kedgene Biotechnology
  • 23. ANI Pharmaceuticals
  • 24. apceth Biopharma
  • 25. Applied Biological Materials
  • 26. Arbele
  • 27. Arcline Investment Management
  • 28. Argos Therapeutics
  • 29. Aspire Health Science
  • 30. Astellas Pharma
  • 31. Asterias Biotherapeutics
  • 32. AstraZeneca
  • 33. Atara Biotherapeutics
  • 34. ATCC
  • 35. Athersys
  • 36. Atlantis Bioscience
  • 37. Atreca Therapeutics
  • 38. Aurora Biopharma
  • 39. Austrianova
  • 40. Autolus
  • 41. Avantor
  • 42. AVAX Technologies
  • 43. Axol Bioscience
  • 44. Basic Pharma
  • 45. Baxalta
  • 46. Baxter
  • 47. BD Biosciences
  • 48. Beijing Biohealthcare Biotechnology
  • 49. Beijing Doing Biomedical
  • 50. Beijing Immunochina Medical Science & Technology
  • 51. Beijing Sanwater Biological Technology
  • 52. Beijing Tricision Biotherapeutics
  • 53. Beike Biotechnology
  • 54. Bellicum Pharmaceuticals
  • 55. Bio Elpida
  • 56. BioAtla
  • 57. BioCardia
  • 58. BioCare
  • 59. BioCentriq
  • 60. Bio-Connect
  • 61. Bioinova
  • 62. Biological Industries
  • 63. BioNTech
  • 64. BioRestorative Therapies
  • 65. Bio-Techne
  • 66. bluebird bio
  • 67. Bone Therapeutics
  • 68. BrainStorm Cell Therapeutics
  • 69. Bristol-Myers Squibb
  • 70. C3i (Center of Excellence for Cellular Therapy)
  • 71. Caladrius Biosciences
  • 72. Capricor Therapeutics
  • 73. Captain T Cell
  • 74. CardioCell
  • 75. Carina Biotech
  • 76. CARsgen Therapeutics
  • 77. CAR-T (Shanghai) Biotechnology
  • 78. Cartherics
  • 79. Catalent Biologics
  • 80. Celgene
  • 81. Celixir
  • 82. Cell and Gene Therapy Catapult
  • 83. Cell Applications
  • 84. Cell Biologics
  • 85. Cell Biotech
  • 86. Cell Genesys
  • 87. Cell Therapies
  • 88. Cellaria
  • 89. Cell-Easy
  • 90. Cellectis
  • 91. Cellex Cell Professionals
  • 92. CellGenix
  • 93. Cellin Technologies
  • 94. Cellmed
  • 95. CellMP (A subsidiary of Emmecell)
  • 96. CELLnTEC Advanced Cell Systems
  • 97. CellPraxis
  • 98. CellProtect Nordic Pharmaceuticals
  • 99. CellProthera
  • 100. Cells Online
  • 101. Cellular Biomedicine Group
  • 102. Cellular Engineering Technologies
  • 103. Cellular Therapeutics
  • 104. Celonic
  • 105. Celprogen
  • 106. Celularity
  • 107. Celyad
  • 108. Censo Biotechnologies
  • 109. CHA Biolab
  • 110. Chengdu MedGenCell
  • 111. China Regenerative Medicine International
  • 112. CiMaas
  • 113. Clean Cells
  • 114. CO.DON
  • 115. Cogent Biosciences
  • 116. Cognate BioServices
  • 117. CoImmune
  • 118. Cook MyoSite
  • 119. Corestem
  • 120. Corning
  • 121. Creative Biolabs
  • 122. CRISPR Therapeutics
  • 123. Cyagen Biosciences
  • 124. Cytiva (A subsidiary of Danaher)
  • 125. Cytopeutics
  • 126. CytoSen Therapeutics (Acquired by Kiadis Pharma)
  • 127. Cytovac
  • 128. CyTuVax
  • 129. Daiichi Sankyo
  • 130. DanDrit Biotech
  • 131. DCPrime
  • 132. Delta-Vir
  • 133. Dendreon
  • 134. DiscGenics
  • 135. ElevateBio
  • 136. Eli Lilly
  • 137. Endocyte
  • 138. Eureka Therapeutics
  • 139. Eutilex
  • 140. Ever Union Biotechnology
  • 141. EXUMA Biotech
  • 142. Fate Therapeutics
  • 143. Ferrer Internacional
  • 144. Fibrocell Technologies
  • 145. Five Prime Therapeutics
  • 146. Formula Pharmaceuticals
  • 147. Fortress Biotech
  • 148. Fosun Kite Biotechnology
  • 149. Froceth
  • 150. Fujilfim Cellular Dynamics
  • 151. Fujifilm
  • 152. Gadeta
  • 153. Gamida Cell
  • 154. GC Cell (Formerly known as Green Cross Cell)
  • 155. Gemini Bio
  • 156. GenCure (A subsidiary of BioBridge Global)
  • 157. Genentech
  • 158. GenIbet Biopharmaceuticals
  • 159. Genzyme
  • 160. GigaGen
  • 161. GlaxoSmithKline
  • 162. Global Cell Med
  • 163. Glycostem Therapeutics
  • 164. Gradalis
  • 165. Green Cross
  • 166. GRI Bio
  • 167. Guangzhou Trinomab Biotech
  • 168. Heat Biologics
  • 169. Hebei Senlang Biotechnology
  • 170. Hemostemix
  • 171. HengRui YuanZheng Bio-Technology
  • 172. HiMedia Laboratories
  • 173. Histocell
  • 174. Histogenics
  • 175. Holostem Terapie Avanzate
  • 176. Hunan Zhaotai Yongren Biotech
  • 177. IBA Lifesciences
  • 178. iCarTAB BioMed
  • 179. iCell Gene Therapeutics
  • 180. Immatics
  • 181. Immune Therapeutics
  • 182. Immunicum
  • 183. ImmunoCellular Therapeutics
  • 184. Immunocore
  • 185. Immunovative Therapies
  • 186. Immutep
  • 187. IncoCell Tianjin (wholly-owned subsidiary of Boyalife Group)
  • 188. Incysus
  • 189. Innoprot
  • 190. Innovative Cellular Therapeutics
  • 191. Inovio Pharmaceuticals
  • 192. inRegen
  • 193. Intellia Therapeutics
  • 194. International Stem Cell Corporation
  • 195. InVitria
  • 196. Iovance Biotherapeutics
  • 197. Irvine Scientific (Acquired by FUJIFILM)
  • 198. ISTO Technologies
  • 199. Ivy Life Sciences
  • 200. iXCells Biotechnologies
  • 201. Janssen
  • 202. Japan Tissue Engineering
  • 203. Juno Therapeutics
  • 204. JW Biotechnology
  • 205. JW CreaGene
  • 206. Kadimastem
  • 207. Kangstem Biotech
  • 208. KBI Biopharma
  • 209. Kiadis Pharma
  • 210. Kiromic
  • 211. Kite Pharma
  • 212. Kuur Therapeutics
  • 213. LAgen Laboratories
  • 214. Laurus Bio (Formerly known as Richcore Lifesciences)
  • 215. Laurus Labs
  • 216. Legend Biotech
  • 217. Leucid Bio
  • 218. Lifecells
  • 219. Lineage Cell Therapeutics
  • 220. Lion TCR
  • 221. Living Pharma
  • 222. Longeveron
  • 223. Lonza
  • 224. Lumos Pharma
  • 225. Lykan Bioscience
  • 226. Marino Biotechnology
  • 227. MaxCyte
  • 228. Medeor Therapeutics
  • 229. Medigene
  • 230. MEDINET
  • 231. MEDIPOST
  • 232. MedVax Technologies
  • 233. Merck Serono
  • 234. Mesoblast
  • 235. Miltenyi Biotec
  • 236. Minaris Regenerative Medicine
  • 237. Minerva Biotechnologies
  • 238. Minovia Therapeutics
  • 239. MolecuVax
  • 240. Moraga Biotechnology
  • 241. Multimmune
  • 242. Mustang Bio
  • 243. Nanjing KAEDI Biotech
  • 244. NantKwest
  • 245. Neopharm
  • 246. Neuralstem
  • 247. Neuromics
  • 248. Nikon CeLL innovation
  • 249. Nkarta
  • 250. Nohla Therapeutics
  • 251. Noile-Immune Biotech
  • 252. Northern Therapeutics
  • 253. Northwest Biotherapeutics
  • 254. Novadip Biosciences
  • 255. Novartis
  • 256. NovaRx (Acquired by Viropro)
  • 257. Novella Clinical
  • 258. Novex Innovations
  • 259. Nucleus Biologics
  • 260. Nuo Therapeutics
  • 261. OhioHealth
  • 262. OiDE BetaRevive
  • 263. Ology Bioservices
  • 264. Oncobiomed
  • 265. Opexa Therapeutics
  • 266. Orchard Therapeutics
  • 267. OrganaBio
  • 268. Osiris Therapeutics
  • 269. Oxford BioMedica
  • 270. PAN-Biotech
  • 271. PDC*line Pharma
  • 272. PELOBiotech
  • 273. PeproTech
  • 274. PersonGen BioTherapeutics
  • 275. Pfizer
  • 276. PharmaBio
  • 277. Pharmicell
  • 278. PhoenixSongs Biologicals
  • 279. Pinze Lifetechnology
  • 280. Pique Therapeutics
  • 281. Pluristem Therapeutics
  • 282. Plus Therapeutics
  • 283. Poseida Therapeutics
  • 284. Precigen
  • 285. Precision BioSciences
  • 286. Preferred Cell Systems™
  • 287. Pregene ShenZhen Biotechnology
  • 288. Primorigen Biosciences (Acquired by Nucleus Biologics)
  • 289. ProMab Biotechnologies
  • 290. Promethera Biosciences
  • 291. PromoCell
  • 292. Provia Laboratories
  • 293. R&D Systems (Formerly known as Atlanta Biologicals)
  • 294. ReachBio Research Labs
  • 295. Regeneris Medical
  • 296. Regeneron
  • 297. Regeneus
  • 298. ReNeuron
  • 299. REPROCELL
  • 300. Rexgenero
  • 301. RHEACELL
  • 302. Riyadh Pharma
  • 303. RoosterBio
  • 304. Roslin Cell Therapies
  • 305. Rubius Therapeutics
  • 306. S.Biomedics
  • 307. Sangamo Therapeutics
  • 308. Sanvitra
  • 309. Saronic Biotechnology
  • 310. Sartorius
  • 311. ScienCell Research Laboratories
  • 312. Sclnow Biotechnology
  • 313. SCM Lifescience
  • 314. Seattle Genetics
  • 315. Sentien Biotechnologies
  • 316. Servier
  • 317. Shanghai Bioray Laboratory
  • 318. Shanghai GeneChem
  • 319. Shanghai Houchao Biotechnology
  • 320. Shanghai iCELL Biotechnology
  • 321. Shanghai Longyao Biotechnology
  • 322. Shanghai Unicar-Therapy Bio-medicine Technology
  • 323. Shenzhen BinDeBio
  • 324. Shenzhen Hornetcorn Biotechnology
  • 325. Shionogi
  • 326. Sigma-Aldrich (Acquired by Merck)
  • 327. Sinobioway Cell Therapy
  • 328. SMT Bio
  • 329. Sorrento Therapeutics
  • 330. SOTIO
  • 331. SQZ Biotech
  • 332. Stem Cell Arabia
  • 333. STEMCELL Technologies
  • 334. StemImmune
  • 335. Stemmatters
  • 336. Sumitomo Dainippon Pharma
  • 337. Super-T Cell Cancer Company
  • 338. Surface Oncology
  • 339. Tactiva Therapeutics
  • 340. Taiwan Bio Therapeutics
  • 341. Takara Bio
  • 342. Takeda Pharmaceutical
  • 343. TapImmune
  • 344. Targazyme
  • 345. TC BioPharm
  • 346. TCR2 Therapeutics
  • 347. Tella
  • 348. Tessa Therapeutics
  • 349. The Discovery Labs Center for Breakthrough Medicines
  • 350. Thermo Fisher Scientific
  • 351. ThermoGenesis
  • 352. Tianhe Stem Cell Biotechnologies
  • 353. TiGenix
  • 354. TILT Biotherapeutics
  • 355. Tmunity Therapeutics
  • 356. TNK Therapeutics
  • 357. TotipotentRX
  • 358. TRACT Therapeutics
  • 359. TransCure BioServices
  • 360. TreeFrog Therapeutics
  • 361. Trinova Biochem
  • 362. Triumvira Immunologics
  • 363. TVAX Biomedical
  • 364. Universal Cells
  • 365. U.S. Stem Cell
  • 366. Vaccinogen
  • 367. Vericel
  • 368. VetStem Biopharma
  • 369. ViroMed
  • 370. Viscofan BioEngineering
  • 371. Vitro Biopharma
  • 372. Waisman Biomanufacturing
  • 373. West Biotherapy
  • 374. Wissenschaftlicher Service Pharma (WiSP)
  • 375. Wuhan Sian Medical Technology
  • 376. WuXi AppTec (WuXi Advanced Therapies)
  • 377. Xcell Therapeutics
  • 378. Xcelthera
  • 379. XEME Biopharma
  • 380. Zelluna Immunotherapy
  • 381. Zimmer Biomet
  • 382. Ziopharm Oncology